Malignant lung cancer carries a poor prognosis with a 5-year survival rate of about 18%. This new method proposes an innovative minimally invasive procedure for the transcutaneous ablation of lung tumor masses with complete removal or significant debulking of the masses. This new procedure could increase lung cancer survival rates and at the same time decrease morbidity and side effects associated with current treatment therapies. It will also provide a viable treatment for a large group of patients that cannot tolerate resection surgery, radiotherapy and chemotherapy, or who have had prior radiation and cannot have additional radiation to that region.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords